CSI Market
Sign In | Register

Nabriva Therapeutics Plc (NBRV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NBRV Annual Cash Flow →
A period-by-period view of cash flow from Nabriva Therapeutics Plc to Jun 30 2022 helps clarify how Jun 30 2023's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income-12.06
Depreciation & amortization0.04
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges5.40
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase9.68
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.10
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Interest Income-
Noncash Interest Expense0.06
Increase Decrease In Long Term Receivables-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Other Receivables And Prepaid Expenses1.19
Income taxes0.48
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable8.60
Increase (Decrease) in Accrued Liabilities-5.36
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-0.13
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-5.11
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Certificates Of Deposit-
Proceeds From Maturities Certificates Of Deposit-
Payment For Business Combination Transaction Cost Net Of Cash Acquired Investing Activities-
Changes In Restricted Cash-0.05
Payments Proceeds For Other Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-4.85
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Other Proceeds From Shareholders-
Proceeds From Silent Partnership-
Repayments Of Participation Rights-
Equity Transaction Costs Included In Accounts Payable And Accrued Expenses-
Proceeds From Issuance Of Common Stock And Warrants-
Payments Or Adjustments Of Stock Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4.85
Effect of exchange rate on cash flow-0.27
Discontinued operations0.00
Free Cash Flow-5.11
Total Cash Flow-10.28
4 historic quarters locked

Sign in to unlock the full Nabriva Therapeutics Plc cash flow history.

Sign In Create Free Account

About Nabriva Therapeutics Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-016524

Figures are derived from filed reports and may be restated. Historical data is subject to revision.